Stock Price Forecast

March 27, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Repligen Corp. chart...

About the Company

repligen corporation is a life sciences company focused on the development, production and commercialization of products used in the process of manufacturing biological drugs. our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. we are a leading manufacturer of protein a, a critical reagent used to manufacture monoclonal antibody-based therapeutics. we also supply several growth factor products used to increase cell culture productivity in biomanufacturing. in the burgeoning area of disposable biomanufacturing technologies, we have developed and market a series of opus™ (open platform user specified) single-use chromatography columns used in the biologics purification process. repligen’s corporate headquarters are located in waltham, ma, usa; we have an additional manufacturing facility in lund, sweden.

CEO

Anthony Hunt

Exchange

NASDAQ

Website

https://www.repligen.com/

$44M

Total Revenue

1K

Employees

$10B

Market Capitalization

132.29

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $RGEN News

What's Going On With Life Science-Focused Repligen Stock Today?

on MSN ago, source:

Repligen Corporation (NASDAQ:RGEN) reported fourth-quarter 2023 adjusted EPS of $0.33, in line with the consensus estimate.

Repligen (RGEN) Price Target Increased by 8.15% to 203.98

1mon ago, source: Fintel on MSN

Repligen Background Information (This description is provided by the company.) Repligen Corporation is a global life sciences ...

Repligen Appoints Maggie A. Pax to Board of Directors

9d ago, source:

Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors of life sciences industry executive Maggie A. Pax. This appointment expands the size of Repligen’s board ...

Repligen Corp RGEN

6d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Repligen Corp RGN

1mon ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Repligen to Report Fourth Quarter and Full Year 2023 Financial Results

1mon ago, source: Business Insider

WALTHAM, Mass., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its fourth quarter 2023 financial results on Wednesday ...

Repligen: Q4 Earnings Snapshot

1mon ago, source: Houston Chronicle

WALTHAM, Mass. (AP) — WALTHAM, Mass. (AP) — Repligen Corp. (RGEN) on Wednesday reported a loss of $25.5 million in its fourth quarter. The Waltham, Massachusetts-based company said it had a ...

Repligen Corp CEO Anthony Hunt Sells 16,707 Shares

16d ago, source:

Repligen Corp (NASDAQ:RGEN), a bioprocessing company focused on the development, manufacture, and commercialization of ...

Repligen Corp.

21d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...